Once the undisputed leader of China’s health wine market, Hainan Yedao (Group) Co., Ltd. now finds itself in a precarious struggle for survival. The company, known by its ticker *ST Yedao on the Shanghai Stock Exchange, is racing to defend a critical 300-million-yuan revenue threshold. Failing to exceed this benchmark in its audited 2025 financial reports would trigger an automatic delisting, ending a two-decade tenure as a public entity.
While the company’s preliminary results for 2025 claim a revenue of 370 million yuan, regulatory scrutiny has cast a long shadow over these figures. The Shanghai Stock Exchange and independent auditors have raised red flags regarding the authenticity of these earnings. Specifically, investigators are looking into whether the company engaged in 'channel stuffing'—the practice of bloating sales figures by flooding distributors with inventory that never reaches the end consumer.
The centerpiece of the controversy is the 'Lugui Jiu' (Deer and Tortoise Wine) premium series, which was launched as late as September 2025. Despite its short time on the market, the product reportedly generated 175 million yuan, accounting for over half of the company’s total liquor revenue. However, a recent audit found that only 20% to 40% of these goods had actually been sold to consumers, with the vast majority remaining stagnant in distributor warehouses.
Adding to the skepticism is the sudden emergence of 'ghost' clients. Analysis of Yedao’s top ten customers reveals that several high-volume buyers were incorporated only months or even weeks before placing multi-million-yuan orders. For instance, entities like Hebei Yuebo Trading and Guangdong Yilukang were both established in September 2025 and immediately became top-tier revenue contributors, a trajectory that defies standard business development cycles.
This administrative fragility is not a new development for the Hainan-based firm. Over the past decade, the company transitioned from a state-owned enterprise to a vehicle for private investors who pivoted aggressively into unrelated sectors like real estate and sauce-aroma baijiu. These distractions allowed rivals such as Jing Jiu to seize the market, leaving Yedao’s core health wine business to wither into its current state of managed decline.
Beyond the revenue concerns, the company’s internal governance is in shambles. Auditors have previously issued 'negative' opinions on Yedao’s internal controls, citing a total lack of credit reviews for new distributors and a leadership structure where key roles are held by part-time or overextended managers. If the 2025 audit fails to verify the effectiveness of recent 'rectifications,' the company will face delisting regardless of its final revenue tally.